Trials / Completed
CompletedNCT06006598
A Study to Test How Well Different Doses of BI 1584862 Are Tolerated by Healthy Men
Safety, Tolerability, and Pharmacokinetics of Multiple Rising Oral Doses of BI 1584862 in Healthy Subjects (Single-blind, Randomised, Placebo-controlled, Parallel Group Design)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- Male
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The main objectives of this trial are to investigate safety, tolerability, and pharmacokinetics of BI 1584862 in healthy male subjects following administration of multiple rising doses.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BI 1584862 | BI 1584862 |
| DRUG | Placebo matching BI 1584862 | Placebo matching BI 1584862 |
| DRUG | midazolam | midazolam |
Timeline
- Start date
- 2023-08-28
- Primary completion
- 2024-05-05
- Completion
- 2024-05-05
- First posted
- 2023-08-23
- Last updated
- 2024-05-14
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT06006598. Inclusion in this directory is not an endorsement.